Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections

Transpl Infect Dis. 2023 Nov:25 Suppl 1:e14101. doi: 10.1111/tid.14101. Epub 2023 Jul 18.

Abstract

Background: Infectious disease physicians may be asked to evaluate and manage a variety of infections in immunocompromised hosts undergoing hematopoietic cell transplant (HCT) and cellular therapies. Over the last decade, several advances in cellular therapy have occurred, with implications for the types of infectious complications that may be seen.

Aims: The purpose of this review is to update the infectious disease physician on newer advances in HCT and cellular therapy, including haploidentical transplant, expanding indications for transplant in older individuals and children, and chimeric antigen receptor T-cells. We will review how these advances might influence infectious disease complications following HCT. We will also provide a perspective that infectious disease physicians can use to evaluate the degree of immune suppression in an individual patient to help determine the type of infections that may be encountered.

Keywords: chimeric antigen receptor t-cell; haploidentical; hematopoietic cell transplant; older adults; pediatrics; serotherapy; stem cell transplant.

Publication types

  • Review

MeSH terms

  • Aged
  • Child
  • Communicable Diseases*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Immunosuppression Therapy
  • Opportunistic Infections*
  • Transplantation, Homologous